HomeCompareAGE vs KMB

AGE vs KMB: Dividend Comparison 2026

AGE yields 18.02% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGE wins by $18.7K in total portfolio value
10 years
AGE
AGE
● Live price
18.02%
Share price
$11.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.6K
Annual income
$5,421.64
Full AGE calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — AGE vs KMB

📍 AGE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGEKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGE + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGE pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGE
Annual income on $10K today (after 15% tax)
$1,531.53/yr
After 10yr DRIP, annual income (after tax)
$4,608.39/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, AGE beats the other by $169.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGE + KMB for your $10,000?

AGE: 50%KMB: 50%
100% KMB50/50100% AGE
Portfolio after 10yr
$55.3K
Annual income
$5,321.99/yr
Blended yield
9.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

AGE
No analyst data
Altman Z
-20.5
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGE buys
0
KMB buys
0
No recent congressional trades found for AGE or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGEKMB
Forward yield18.02%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$64.6K$45.9K
Annual income after 10y$5,421.64$5,222.34
Total dividends collected$34.8K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: AGE vs KMB ($10,000, DRIP)

YearAGE PortfolioAGE Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$12,502$1,801.80$11,314$614.45+$1.2KAGE
2$15,482$2,105.21$12,867$760.19+$2.6KAGE
3$19,002$2,436.52$14,713$945.27+$4.3KAGE
4$23,127$2,794.89$16,924$1,181.90+$6.2KAGE
5$27,925$3,179.07$19,596$1,486.64+$8.3KAGE
6$33,468$3,587.47$22,850$1,882.16+$10.6KAGE
7$39,829$4,018.19$26,849$2,399.80+$13.0KAGE
8$47,086$4,469.06$31,812$3,083.36+$15.3KAGE
9$55,319$4,937.71$38,033$3,994.72+$17.3KAGE
10$64,613$5,421.64$45,918$5,222.34+$18.7KAGE

AGE vs KMB: Complete Analysis 2026

AGEStock

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Full AGE Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this AGE vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGE vs SCHDAGE vs JEPIAGE vs OAGE vs KOAGE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.